Zobrazeno 1 - 10
of 33
pro vyhledávání: '"35"'
Autor:
A. J. Bredenoord, André J.P.M. Smout, Marlies P. Schijven, Jeroen M Schuitenmaker, José M. Conchillo, Froukje B. van Hoeij, Eric J. Hazebroek, Jan Tack
Publikováno v:
Gut, 71(1), 10-15. BMJ Publishing Group
ObjectiveThere is no evidence-based treatment for persistent dysphagia after laparoscopic fundoplication. The aim of this study was to evaluate the effect of pneumatic dilation on persistent dysphagia after laparoscopic fundoplication.DesignWe perfor
Autor:
T Kawabe, Hiroyuki Isayama, Hideo Yoshida, Masao Omata, Motohisa Tada, Naoki Sasahira, Yutaka Komatsu, Kenji Hirano, Shuichiro Shiina, Ryosuke Tateishi, Nobuo Toda
Publikováno v:
Gut. 54(5)
Background and aims: Percutaneous tumour ablation (PTA), such as ethanol injection and radiofrequency ablation, is now recognised as a primary treatment for hepatocellular carcinoma (HCC). Although PTA is a relatively safe procedure, it can cause bil
Autor:
Rakesh Kalapala, Zaheer Nabi, Rajesh Gupta, Prateek Sharma, D. Nageshwar Reddy, Arun Karyampudi, G Venkat Rao, Nitin Jagtap, Santosh Darisetty, Rajesh Goud, Mohan Ramchandani, Sundeep Lakhtakia
Publikováno v:
Gut. 71(4)
BackgroundThe majority of endoscopic antireflux procedures for GERD are cumbersome to use and randomised long-term data are sparse. We conducted such a trial to determine the efficacy and safety of a novel, easy to use endoscopic full-thickness fundo
Autor:
Steve Lewitzky, Wolfgang Hueber, Marc Vandemeulebroecke, Gervais Tougas, Bjoern Mellgard, Arthur P. Bertolino, Jacek Karczewski, Stephan Bek, Jan Wehkamp, Nicole Pezous, Brian G. Feagan, Gerard Bruin, Marco Londei, Simon Travis, Michael D Yao, Bruce E. Sands, Walter Reinisch, Peter D.R. Higgins, Claudia Berger, Marek Karczewski
Publikováno v:
Gut. 61:1693-1700
OBJECTIVE: The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease. DESIGN: In a double-blind, randomised, placebo-controlled proof-of-concept study,
Autor:
Arthur Schatzkin, Christian C. Abnet, Mark G. O'Doherty, Albert R. Hollenbeck, Neal D. Freedman
Publikováno v:
Gut. 61:1261-1268
Objective The incidence of oesophageal adenocarcinoma (EAC) has increased rapidly over the past 40 years and accumulating evidence suggests that obesity, as measured by body mass index (BMI), is a major risk factor. It remains unclear whether abdomin
Autor:
Henrik Toft Sørensen, Thomas A. Ullman, David T. Rubin, Robert S. Sandler, Michael D. Kappelman, Lars Pedersen, John A. Baron, Erzsébet Horváth-Puhó
Publikováno v:
Kappelman, M D, Horváth-Puhó, E, Sandler, R S, Rubin, D T, Ullman, T A, Pedersen, L, Baron, J A & Sørensen, H T 2011, ' Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study ', Gut, vol. 60, pp. 937-43 . https://doi.org/10.1136/gut.2010.228585
Background Recommendations for venous thromboembolism (VTE) prophylaxis in patients with inflammatory bowel disease (IBD) can be refined by incorporating patient-specific risk factors. Objectives To determine the risk of deep venous thrombosis (DVT)
Autor:
Stephen J. O'Keefe, Marek Pertkiewicz, Johane P. Allard, Richard Gilroy, Palle Jeppesen, Bernard Messing
Publikováno v:
Gut
Background and aims Teduglutide, a GLP-2 analogue, may restore intestinal structural and functional integrity by promoting repair and growth of the mucosa and reducing gastric emptying and secretion, thereby increasing fluid and nutrient absorption i
Autor:
Wolfgang Stremmel, Lorenz Theilmann, Adolf Stiehl, S Engler, C. Elsing, Christa Flechtenmacher
Publikováno v:
Gut. 52:688-693
Background: We present nine patients with progressive sclerosing cholangitis after septic shock. Patients: All nine patients had previously required long term treatment in an intensive care unit for septic shock: two patients with polytrauma, five wi
Autor:
Jan Wohlfahrt, Ebbe Langholz, Saima Basit, Mikael Andersson, Tine Jess, Christine Rungoe, Nete Munk Nielsen
Publikováno v:
Gut. 63(10)
Treatment possibilities have changed in inflammatory bowel disease (IBD). We assessed changes in medical treatment and surgery over time and impact of medications on risk of surgery in a population-based cohort.48 967 individuals were diagnosed with
Publikováno v:
Gut. 45:295-300
BACKGROUND AND AIMSTo develop and assess a disease specific instrument for measuring health related quality of life (HRQL) in patients with chronic liver disease (CLD).METHODSBased on responses from 60 patients with chronic liver disease, from 20 liv